Midas Capital has invested in KORTUC Inc., a California-based biotechnology firm specializing in innovative cancer treatment technologies.

Target Company Overview

KORTUC Inc., founded in Japan and currently headquartered in Palo Alto, California, is a biotechnology firm specializing in radiation therapy for cancer treatment. The company is dedicated to advancing its proprietary radiation sensitizers which improve the efficacy of radiotherapy by enhancing the tumor's response to treatment, particularly in oxygen-deprived environments that contribute to resistance against radiation therapy.

KORTUC has established collaborations with leading cancer centers globally to bring its innovative therapies to patients worldwide. Its techniques have demonstrated clinical success, with more than 1,000 cases across various solid tumors completed in Japan. The company is currently engaged in a Phase II clinical trial in partnership with the Institute of Cancer Research (ICR) in London, as well as major cancer centers in the UK and India. Further expansions of clinical trials for rectal and cervical cancer are planned in the UK, France, the United States, India, and Thailand.

Industry Overview

The biotechnology and pharmaceutical sectors in the United States are robust and continually evolving, focusing on innovative drug development and advanced therapeutic techn